trimetrexate has been researched along with Colorectal Neoplasms in 19 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We tested the hypothesis that the combination of trimetrexate (TMTX) and capecitabine (CAP) would be active in patients with previously treated metastatic colorectal cancer (CRC)." | 9.11 | A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. ( Earle, M; Evans, T; Ferri, W; Friedland, D; Jacobs, SA; Matin, K; Pinkerton, R; Ramanathan, RK; Richards, T; Troetschel, M; Volkin, R; Wieand, S; Wong, MK, 2005) |
| "Two randomised studies were performed with trimetrexate (TMTX) as a biochemical modulator of 5-fluorouracil (5-FU)/leucovorin (LV) in advanced colorectal cancer (ACC), one in Europe and one in the United States." | 9.10 | Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. ( Blanke, CD; Hammershaimb, L; Punt, CJ; Zhang, J, 2002) |
| "Trimetrexate (TMQ), a non-classical folate antagonist, was studied in a randomized controlled trial in patients with advanced colorectal cancer and without prior chemotherapy." | 9.08 | A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study. ( Brown, TD; Fleming, TR; Goodman, PJ; Macdonald, JS; O'Rourke, T; Pugh, RP, 1995) |
| "5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer." | 8.80 | Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998) |
| "Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens." | 8.80 | Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998) |
| "Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV)." | 6.70 | Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. ( Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J, 2002) |
| "Trimetrexate is a nonclassical antifolate that has demonstrated antitumor activity against a number of malignancies, including those resistant to the classical antifolate methotrexate." | 6.40 | Trimetrexate: review and current clinical experience in advanced colorectal cancer. ( Blanke, CD; Messenger, M; Taplin, SC, 1997) |
| "The purpose of this report is to evaluate the efficacy and toxicity (Tx) of a double modulation of 5-fluorouracil (5-FU) by trimetrexate (TMTX) and leucovorin (LV) in patients with advanced recurrent (inoperable) or metastatic colorectal cancer (ACC)." | 5.11 | Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. ( Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004) |
| "We tested the hypothesis that the combination of trimetrexate (TMTX) and capecitabine (CAP) would be active in patients with previously treated metastatic colorectal cancer (CRC)." | 5.11 | A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. ( Earle, M; Evans, T; Ferri, W; Friedland, D; Jacobs, SA; Matin, K; Pinkerton, R; Ramanathan, RK; Richards, T; Troetschel, M; Volkin, R; Wieand, S; Wong, MK, 2005) |
| "Two randomised studies were performed with trimetrexate (TMTX) as a biochemical modulator of 5-fluorouracil (5-FU)/leucovorin (LV) in advanced colorectal cancer (ACC), one in Europe and one in the United States." | 5.10 | Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. ( Blanke, CD; Hammershaimb, L; Punt, CJ; Zhang, J, 2002) |
| " A regimen of sequential TMTX, FA and 5-fluorouracil (5-FU) has shown efficacy in patients with colorectal cancer." | 5.09 | Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO. ( Berdel, WE; Haboubi, N; Hohenberger, P; Kreuser, ED; Lochs, H; Szelényi, H; Thiel, E, 2000) |
| "Trimetrexate (TMQ), a non-classical folate antagonist, was studied in a randomized controlled trial in patients with advanced colorectal cancer and without prior chemotherapy." | 5.08 | A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study. ( Brown, TD; Fleming, TR; Goodman, PJ; Macdonald, JS; O'Rourke, T; Pugh, RP, 1995) |
| "5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer." | 4.80 | Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998) |
| "Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens." | 4.80 | Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998) |
| "For nearly four decades, 5-fluorouracil (5-FU) has been the mainstay of treatment for colorectal cancer." | 4.80 | Where do we stand with 5-fluorouracil? ( Büchele, T; Dempke, W; Grothey, A; Schmoll, HJ, 1999) |
| "Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.70 | Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. ( Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J, 2002) |
| "Trimetrexate (TMTX) is a dihydrofolate reductase inhibitor, which, like methotrexate (MTX), has been shown to potentiate fluorouracil (FU) cytotoxicity by increasing phosphoribosylpyrophosphate (PRPP) levels." | 2.67 | Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. ( André, M; Bertino, JR; Conti, JA; Goker, E; Kemeny, N; Ragusa, K; Seiter, K; Tong, W, 1994) |
| "Trimetrexate was administered at a median daily dose of 15 mg/m2 (range, 6-22 mg/m2) intravenously for five days every three weeks." | 2.67 | A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Boman, BM; Faintuch, JS; Jackson, DE; Krakoff, IH; Levin, B; Patt, YZ, 1990) |
| "Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment." | 2.41 | New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. ( Holen, KD; Saltz, LB, 2001) |
| "Approximately 50% of patients with colorectal cancer develop locally recurrent or distant metastatic disease during the course of their illness and eventually die." | 2.40 | Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. ( Borud, K; Isacoff, WH, 1997) |
| "Trimetrexate is a nonclassical antifolate that has demonstrated antitumor activity against a number of malignancies, including those resistant to the classical antifolate methotrexate." | 2.40 | Trimetrexate: review and current clinical experience in advanced colorectal cancer. ( Blanke, CD; Messenger, M; Taplin, SC, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (57.89) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Machiavelli, MR | 1 |
| Salum, G | 1 |
| Pérez, JE | 1 |
| Ortiz, EH | 1 |
| Romero, AO | 1 |
| Bologna, F | 1 |
| Vallejo, CT | 1 |
| Lacava, JA | 1 |
| Dominguez, ME | 1 |
| Leone, BA | 1 |
| Matin, K | 1 |
| Jacobs, SA | 1 |
| Richards, T | 1 |
| Wong, MK | 1 |
| Earle, M | 1 |
| Evans, T | 1 |
| Troetschel, M | 1 |
| Ferri, W | 1 |
| Friedland, D | 1 |
| Pinkerton, R | 1 |
| Volkin, R | 1 |
| Wieand, S | 1 |
| Ramanathan, RK | 1 |
| Conti, JA | 1 |
| Kemeny, N | 2 |
| Seiter, K | 1 |
| Goker, E | 1 |
| Tong, W | 1 |
| André, M | 1 |
| Ragusa, K | 1 |
| Bertino, JR | 2 |
| Brown, TD | 1 |
| Fleming, TR | 1 |
| Goodman, PJ | 1 |
| Macdonald, JS | 1 |
| Pugh, RP | 1 |
| O'Rourke, T | 1 |
| Grem, JL | 1 |
| Voeller, DM | 1 |
| Geoffroy, F | 1 |
| Horak, E | 1 |
| Johnston, PG | 1 |
| Allegra, CJ | 1 |
| Isacoff, WH | 1 |
| Borud, K | 1 |
| Blanke, CD | 3 |
| Messenger, M | 1 |
| Taplin, SC | 1 |
| Ardalan, B | 1 |
| Luis, R | 1 |
| Jaime, M | 1 |
| Franceschi, D | 1 |
| Punt, CJ | 4 |
| Henderson, CA | 1 |
| Schmoll, HJ | 1 |
| Büchele, T | 1 |
| Grothey, A | 1 |
| Dempke, W | 1 |
| Szelényi, H | 1 |
| Hohenberger, P | 1 |
| Lochs, H | 2 |
| Haboubi, N | 1 |
| Berdel, WE | 1 |
| Thiel, E | 1 |
| Kreuser, ED | 1 |
| Shultz, J | 1 |
| Cox, J | 1 |
| Modiano, M | 1 |
| Isaacs, R | 1 |
| Kasimis, B | 1 |
| Schilsky, R | 1 |
| Fleagle, J | 1 |
| Moore, M | 1 |
| Carlin, D | 1 |
| Hammershaimb, L | 3 |
| Haller, D | 1 |
| Keizer, HJ | 1 |
| Douma, J | 1 |
| Skovsgaard, T | 1 |
| Schüller, J | 1 |
| Muller, EW | 1 |
| Ten Napel, CH | 1 |
| Croles, JJ | 1 |
| Zhang, J | 2 |
| Holen, KD | 1 |
| Saltz, LB | 1 |
| Ajani, JA | 1 |
| Abbruzzese, JL | 1 |
| Faintuch, JS | 1 |
| Patt, YZ | 1 |
| Boman, BM | 1 |
| Jackson, DE | 1 |
| Levin, B | 1 |
| Krakoff, IH | 1 |
9 reviews available for trimetrexate and Colorectal Neoplasms
| Article | Year |
|---|---|
Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Flox | 1997 |
Biomodulation of 5-fluorouracil with antifolates.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 1997 |
Trimetrexate: review and current clinical experience in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 1997 |
Biomodulation of Fluorouracil in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clin | 1998 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt | 1998 |
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 1998 |
Where do we stand with 5-fluorouracil?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chro | 1999 |
Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; Fluorour | 2000 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
9 trials available for trimetrexate and Colorectal Neoplasms
| Article | Year |
|---|---|
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2004 |
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2005 |
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Digestive System | 1994 |
A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle | 1995 |
Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2000 |
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2002 |
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2002 |
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Female; F | 2002 |
A phase II study of trimetrexate therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Administration Schedule; Female; Huma | 1990 |
1 other study available for trimetrexate and Colorectal Neoplasms
| Article | Year |
|---|---|
Determinants of trimetrexate lethality in human colon cancer cells.
Topics: Biological Transport; Cell Cycle; Cell Division; Cell Survival; Colorectal Neoplasms; DNA, Neoplasm; | 1994 |